Zydus Lifesciences Reports Strong Q3 & 9M FY26 Growth Across Pharma, Wellness and MedTech Businesses

Zydus Lifesciences Reports Strong Q3 & 9M FY26 Growth Across Pharma, Wellness and MedTech Businesses

Bangalore, Feb 9: Zydus Lifesciences Ltd. today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, reporting robust growth across its key businesses.

Financial Highlights:

• Q3 FY26: Revenue from operations at ₹68,645 mn, up 30% YoY; EBITDA at ₹18,164 mn, up 31% YoY; Net Profit (Adjusted) at ₹11,109 mn, up 9% YoY.

• 9M FY26: Revenue from operations at ₹1,95,614 mn, up 17% YoY; EBITDA at ₹59,207 mn, up 20% YoY; Net Profit (Adjusted) at ₹38,640 mn, up 15% YoY.

• R&D Investments: ₹6,074 mn in Q3 (8.8% of revenue) and ₹15,750 mn in 9M (8.1% of revenue).

• Capex (Organic): ₹4,637 mn in Q3 and ₹13,568 mn in 9M.

Business Updates:

• India Formulations: Revenue at ₹17,094 mn, up 13% YoY; chronic and super specialty segments continue to lead growth.

• North America Formulations: Revenue at ₹28,043 mn, up 16% YoY; multiple new product launches and approvals, including Zycubo® for Menkes disease.

• International Markets: Revenue at ₹7,881 mn, up 38% YoY with broad-based regional growth.

• API Business: Revenue at ₹2,143 mn, up 26% YoY.

• Consumer Wellness: Revenue at ₹9,578 mn, up 113% YoY with full consolidation of Comfort Click Limited.

• MedTech: Revenue at ₹2,996 mn, following full consolidation of Amplitude Surgical.

Operational and Compliance Highlights:

• USFDA inspections completed with EIR status for Jarod injectable (VAI) and Ahmedabad OSD facility (NAI).

• CE mark approval received for proprietary ‘Andy’ robotic surgical system.

Innovation Pipeline Updates:

• NCE Research: Preparing NDA filing for Saroglitazar Magnesium with the USFDA.

• Biotech: Phase III trial approved for second biosimilar antibody drug conjugate in India.

• Vaccines: Phase II trial initiated for Bivalent Typhoid Conjugate Vaccine; awarded rabies and typhoid vaccine supply tenders for PAHO and UNICEF.

• US Specialty & Biosimilars: Licensing and commercialization agreements for novel 505(b)(2) oncology product and biosimilar Pembrolizumab; BLA approval for Nufymco® (biosimilar Ranibizumab).

Commenting on the results, Dr. Sharvil Patel, Managing Director, said:

“Our robust performance across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results. Anchored in patient centricity, supported by compliance and an agile supply chain, we remain focused on consistent execution and driving long-term shareholder value.”

Zydus Lifesciences continues to strengthen its pharma, wellness, and medtech portfolios, delivering innovative solutions to global markets while creating sustainable value for shareholders.